This clinical trial is focused on studying infections in the bloodstream caused by a type of bacteria called Staphylococcus aureus. These infections are often related to the use of catheters, which are tubes inserted into the body to deliver or remove fluids. The study is comparing a single dose of a medication called Dalbavancin, given through an infusion, to the standard antibiotic treatments that are usually given for 14 days. The goal is to see if Dalbavancin is as effective as the standard treatments in curing the infection without it coming back.
Participants in the study will receive either the single dose of Dalbavancin or the standard antibiotics. The study will monitor the participants for 30 days to check for signs of infection and ensure the infection does not return. The study will also look at other factors such as the time it takes for the infection to clear from the blood, the duration of hospital stays, and any side effects experienced by the participants.
The study aims to provide valuable information on whether a single dose of Dalbavancin can be a simpler and effective alternative to the longer standard antibiotic treatments for catheter-related bloodstream infections caused by Staphylococcus aureus. This could potentially lead to shorter treatment times and fewer hospital visits for patients in the future.
France 
